ARTICLE | Company News
Baxter's Rixubis gets CHMP nod for hemophilia B
October 25, 2014 12:56 AM UTC
EMA's CHMP recommended marketing authorization of Rixubis ( BAX 326) from Baxter International Inc. (NYSE:BAX) to treat and prevent bleeding in patients with hemophilia B. Approval will include a pharmacovigilance plan. ...